Evercore ISI analysts upgraded CRISPR Therapeutics stock from an In Line to an Outperform rating and increased the price target significantly to $99 from the previous $60. The upgrade comes as Evercore ISI anticipates pivotal developments that could mark the beginning of a transformative period for the company.

Evercore ISI analyst Liisa Bayko upgraded Crispr Therapeutics (CRSP) to Outperform from In Line with a price target of $99, up from $60.

Evercore ISI has upgraded CRISPR Therapeutics (NASDAQ:CRSP) to outperform from in line, citing upcoming catalysts. The investment firm said it was now including the CTX320 and CTX310 in vivo programs in its price target,

Evercore ISI analyst Liisa Bayko raised the price target for CRISPR Therapeutics from $60.00 to $99.00. Bayko's optimism is driven by upcoming catalysts that could mark a new chapter for the company.